Forecast Period 
Market Size (Base Year) 
Market Size (Forecast Year)
CAGRGlobal Neurodegenerative Disorder Therapeutics Market, By Indication (Multiple sclerosis, Alzheimer’s Disease, Parkinson’s Disease, Huntington’s Disease, Others), Drug Glass (Immunomodulator, Interferons, Decarboxylase Inhibitors, Dopamine Agonists, Others), Route of Administration (Oral, Injection, Transdermal), End- User (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy) – Industry Trends and Forecast to 2029.
Neurodegenerative Disorder Therapeutics Market Analysis and Size
World Population Prospects predicts that by 2050, there will be 2.1 billion individuals over the age of 60 and that the number of persons over the age of 80 would triple to 425 million. 5.8 million Americans currently have Alzheimer's disease, and by 2050, the figure is expected to reach 14 million, according to the Alzheimer's Association. The market is driven by the rising demand for treatments for neurodegenerative disorders as a result of the incidence of neurodegenerative illnesses among the ageing population.
Data Bridge Market Research analyses that the neurodegenerative disorder therapeutics market which was USD 14.66 billion in 2021, would rocket up to USD 22.79 billion by 2029, and is expected to undergo a CAGR of 5.67% during the forecast period 2022 to 2029. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Neurodegenerative Disorder Therapeutics Market Scope and Segmentation
|
Report Metric |
Details |
|
Forecast Period |
2022 to 2029 |
|
Base Year |
2021 |
|
Historic Years |
2020 (Customizable to 2014 - 2019) |
|
Quantitative Units |
Revenue in USD Billion, Volumes in Units, Pricing in USD |
|
Segments Covered |
Indication (Multiple sclerosis, Alzheimer’s Disease, Parkinson’s Disease, Huntington’s Disease, Others), Drug Glass (Immunomodulator, Interferons, Decarboxylase Inhibitors, Dopamine Agonists, Others), Route of Administration (Oral, Injection, Transdermal), End- User (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy) |
|
Countries Covered |
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America |
|
Market Players Covered |
Biogen (U.S.), Merck Sharp & Dohme Corp (U.S.), Novartis AG (Switzerland), Teva Pharmaceutical Industries Ltd. (Israel), Orion Corporation (Finland), UCB S.A. (Belgium), ACADIA Pharmaceuticals Inc. (U.S.), Mitsubishi Chemical Group Corporation (Japan), H. Lundbeck A/S (Denmark), Denali Therapeutics (U.S.), Aquinnah Pharmaceuticals (Japan), Prevail Therapeutics (U.S.), AZTherapies, Inc. (U.S.) |
|
Market Opportunities |
|
Market Definition
A variety of fatal diseases known as "neurodegenerative disorders" predominantly affect the neurons in the human brain and cause the progressive degeneration or death of nerve cells. The field of therapeutics for neurodegenerative disorders focuses on the production and research of medications and treatments that halt or reduce the neurodegenerative processes of illnesses including Parkinson's, Alzheimer's, Huntington's, and other neurodegenerative disorders.
Neurodegenerative Disorder Therapeutics Market Dynamics
Drivers
- Rise in prevalence of neurodegenerative diseases
Increased financing for neurodegenerative disease research is anticipated to boost market expansion. The market for neurodegenerative disorder therapeutics is expected to grow rapidly from 2022 to 2029 as a result of a number of additional factors, including an increase in the prevalence of neurodegenerative diseases, an ageing population, a rise in the risk of neurological disorders like Alzheimer's and Parkinson's disease, and a better understanding of the genetic foundations and molecular pathology of neurodegenerative diseases.
- Increase in elderly population
The market for therapies for neurodegenerative disorders is expanding as the prevalence of these diseases among the world's population rises. The rise in the population of elderly people is attributed to the rise in neurodegenerative illnesses.
Opportunities
The development of novel therapies for neurodegenerative disorders through gene and cell therapies and the massive scope for adoption of neurodegenerative disorders therapeutics in emerging nations will act as opportunities for market growth.
Restraints/Challenges
On the other hand, increasing failure rate of neurodegenerative drugs in clinical trials will obstruct the market's growth rate. The dearth of skilled professionals and lack of healthcare infrastructure in developing economies will challenge the market.
This neurodegenerative disorder therapeutics market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the neurodegenerative disorder therapeutics market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
COVID-19 Impact on Neurodegenerative Disorder Therapeutics Market
The COVID-19 impact on the market was considerable since the pandemic affected clinical trial procedures, R&D operations, and pipeline products. As a result, growth during the pandemic was rather moderate despite the existence of a strong late-stage product pipeline. For instance, due to the difficulty of data processing and the effect of COVID-19 on its research and development studies, Biogen postponed the submission of its Alzheimer's medication application to the Food and Drug Administration. As a result of the aforementioned variables, the market under study saw a temporary slowdown in growth during the COVID-19 pandemic.
Recent Development
- In January 2020, Biogen Inc., an America Biotechnology company acquired a novel clinical stage asset, PF-05251749 along with the applications from Pfizer for $75 million.
Global Neurodegenerative Disorder Therapeutics Market Scope
The neurodegenerative disorder therapeutics market is segmented on the basis of indication, drug glass, route of administration and end- user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Indication
- Multiple sclerosis
- Alzheimer’s Disease
- Parkinson’s Disease
- Huntington’s Disease
- Others
Drug Glass
- Immunomodulator
- Interferons
- Decarboxylase Inhibitors
- Dopamine Agonists
- Others
Route of Administration
- Oral
- Injection
- Transdermal
End- User
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
Neurodegenerative Disorder Therapeutics Market Regional Analysis/Insights
The neurodegenerative disorder therapeutics market is analysed and market size insights and trends are provided by country, indication, drug glass, route of administration and end- user as referenced above.
The countries covered in the neurodegenerative disorder therapeutics market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
North America dominates the neurodegenerative disorder therapeutics market due to increasing awareness about the neurodegenerative disorder in the region.
Asia-Pacific is expected to grow at the highest growth rate in the forecast period of 2022 to 2029 due to the rising health awareness.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Competitive Landscape and Neurodegenerative Disorder Therapeutics Market Share Analysis
The neurodegenerative disorder therapeutics market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to neurodegenerative disorder therapeutics market.
Some of the major players operating in the neurodegenerative disorder therapeutics market are:
- Biogen (U.S.)
- Merck Sharp & Dohme Corp (U.S.)
- Novartis AG (Switzerland)
- Teva Pharmaceutical Industries Ltd. (Israel)
- Orion Corporation (Finland)
- UCB S.A. (Belgium)
- ACADIA Pharmaceuticals Inc. (U.S.)
- Mitsubishi Chemical Group Corporation (Japan)
- H. Lundbeck A/S (Denmark)
- Denali Therapeutics (U.S.)
- Aquinnah Pharmaceuticals (Japan)
- Prevail Therapeutics (U.S.)
- AZTherapies, Inc. (U.S.)
SKU-
